Pune, India, 3 rd May, 2019: The global hereditary angioedema treatment market to gain from
increasing incidences of genetic mutation. Recently Fortune Business Insights, published a report
titled, “Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class
(C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application
(Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel
(Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025.” As per the report, the
global hereditary angioedema treatment market was worth US$ 1883.1 Mn in 2017. The global
market is anticipated to expand at a CAGR of 16.8% and reach US$ 6533.3 Mn by the end of 2025.
The report classifies the global hereditary angioedema treatment market in various segments
and offer a comprehensive overview.
According to the report, the hereditary angioedema treatment market in North America was
valued at US$ 1752.2 Mn in 2017. The growth witnessed is attributable to high prevalence of
hereditary angioedema in the region. North America may remain dominant in the global market
through the forecast period (2018-2025) also. Presence of an established healthcare system and
increasing healthcare expenditure are a few factors anticipated to contribute the expansion of
the hereditary angioedema treatment market in North America. The report also predicts the
market in Asia Pacific to witness impressive growth. Increasing medical tourism in nations such
as China and India will create lucrative growth opportunities for the market in the region. Besides
this, increasing number of product innovations in the region backed by high presence of
hereditary angioedema drugs manufacturers will give tailwinds to growth witnessed by the
hereditary angioedema treatment market.
Get Sample PDF:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hereditary-
angioedema-treatment-market-100164
C-1 Esterase Inhibitor Segment to Dominate Global Market During Forecast Period
In terms of drug class, the C-1 esterase inhibitor is the most popular drug and dominated the
global hereditary angioedema treatment market in 2017. The segment accounted for 61.3% of
the global market in 2017. The trend is unlikely to change during the forecast period 2018-2025
owing to the drug’s reliability among patients and practitioners.
Increasing awareness about the disorder and rising prevalence of the hereditary angioedema are
some factors expected to drive the global hereditary angioedema treatment market during the
forecast period. Additionally, technological developments in the hereditary angioedema
treatment devices and equipment is expected to boost the global market.